What is a possible complication for neonates exposed to buprenorphine during gestation?

Neonates exposed to buprenorphine during gestation are at risk for developing Neonatal Abstinence Syndrome (NAS). Buprenorphine is an opioid used for the treatment of opioid use disorder, and when pregnant individuals use it, the medication can cross the placenta and affect the developing fetus. NAS occurs when a baby is born physically dependent on substances that were used by the mother during pregnancy and can manifest with a range of withdrawal symptoms such as irritability, feeding difficulties, tremors, and seizures.

This risk of NAS is significant because it reflects the impact of opioid exposure on the central nervous system and the withdrawal symptoms that may develop shortly after birth, requiring careful monitoring and possible treatment for the newborn. Therefore, recognizing NAS as a complication of buprenorphine exposure is crucial for providing appropriate care and intervention for affected neonates.